Pfizer sweetens offer for Metsera in bidding war against Novo, Bloomberg News reports

Group 1 - Pfizer has submitted an enhanced bid for obesity drug developer Metsera, indicating a strategic move to strengthen its position in the obesity treatment market [1] - The competition between Pfizer and rival Novo Nordisk is intensifying, highlighting the growing importance of obesity drugs in the pharmaceutical industry [1]